Three evidence tiers, clearly separated — because the approved label and real-world use are not the same thing. Every claim is labelled by evidence class and carries its source. Last reviewed .
The approved label. This is the regulatory truth about what is approved — not a claim that other effects don't exist.
Peer-reviewed and conference trials, including off-label work in men and the intranasal studies. Effect sizes and study quality included.
Clinical observation, forums and individual experience — including the publisher's own. Real data about what people do; not proof of efficacy.
A great deal of what the FDA approves and what people actually do diverge. We show both rather than pretending one is the other — and we mark which is which.
Bremelanotide (research name PT-141) is a melanocortin receptor agonist. It is FDA-approved as VYLEESI, a subcutaneous injection, initial U.S. approval 2019 (NDA 210557), for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The label's limitations of use state it is not indicated for HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance.
1.75 mg subcutaneously to abdomen or thigh, at least 45 minutes before anticipated sexual activity; max one dose per 24 hours and max 8 doses per month. Discontinue after 8 weeks if no improvement. Contraindicated in uncontrolled hypertension or known cardiovascular disease. Each dose transiently raises blood pressure by up to +6/+3 mmHg (peaking 2–4 h, resolving ~12 h) and lowers heart rate by up to 5 bpm. Nausea 40% (13% needed anti-emetics, 8% discontinued); focal hyperpigmentation 1% at ≤8 doses/month — 38% with daily dosing, higher in darker skin, and not confirmed to reverse.
Yes — that was its original indication. Bremelanotide was developed as a treatment for male erectile dysfunction before the women's HSDD program. A double-blind, placebo-controlled study of intranasal PT-141 in healthy men and in Viagra-responsive ED patients found a statistically significant erectile response versus placebo at doses above 7 mg, with onset of erection at roughly 30 minutes (median Tmax 0.50 h, half-life 1.85–2.09 h).
Several studies point that way. In men with moderate-to-severe ED where sildenafil gave an adequate erection no more than 50% of the time, subcutaneous bremelanotide produced a mean 28 minutes (4 mg) and 41 minutes (6 mg) of ≥60% base rigidity, versus 6 minutes on placebo. Separately, in 19 men with ED, low-dose intranasal PT-141 plus sildenafil produced an erectile response significantly greater than sildenafil alone — the two act on different pathways, central and vascular.
A large placebo-controlled trial of intranasal bremelanotide in 726 men with ED reported a positive clinical response in about 33.5% on bremelanotide versus 8.5% on placebo (p = 0.03) at doses of 7.5 mg and above — including men who had failed PDE5 inhibitors. The caveat matters: the publishing journal later issued a formal Expression of Concern about that study, so its numbers should be read cautiously, and the intranasal development program was ultimately discontinued. Other smaller controlled work pointed the same direction (51 of 150 patients reporting significantly better results versus 9% on placebo).
PDE5 inhibitors act peripherally, on nitric-oxide signalling in penile vasculature. Bremelanotide acts centrally, activating the MC4 receptor in the hypothalamus and downstream dopaminergic circuits governing sexual motivation — it can produce erection without visual sexual stimulation. Because the mechanism does not depend on nitric oxide, it is theoretically active where NO pathways are impaired, which is the rationale behind the PDE5-nonresponder studies. That is also why the side-effect profile differs: blood pressure, nausea and pigmentation rather than vasodilation.
Intranasal absorption is real and rapid — median Tmax ~0.5 h. Doses in the trials ran up to 20 mg, with up to 20 mg safely administered to healthy male subjects; the erectile response was significant at 10 and 20 mg in Phase I and at 20 mg in Phase IIa. What is not established is a fixed conversion between a nasal dose and the 1.75 mg subcutaneous product: the approved label contains no intranasal data at all, so any "nasal dose equals X mg subcutaneous" claim is an extrapolation, not a label fact.
Yes, and it is small. Goldstein & Goldstein (2024) reported an observational series of 21 men prescribed subcutaneous bremelanotide off-label for mixed sexual dysfunction. Among responders: 52% improved erectile dysfunction, 39% improved low sexual desire, 17% improved difficulty with orgasm, and 39% reported reduced performance anxiety. Uncontrolled, unblinded, n = 21 — hypothesis-generating, not proof.
The evidence that PT-141 can produce erections in men is real but older and thinner than for the approved female indication: several controlled trials, one of them large, plus a small modern observational series. It is not FDA-approved for male ED; the trials used intranasal formulations that differ from today's approved injection; the largest male trial carries an Expression of Concern; and the intranasal program was stopped. Clinicians at sexual-medicine centres do prescribe it off-label, which is lawful. Anyone telling you either "it's approved for men" or "it doesn't work in men" is overstating in opposite directions.
Patient forums and clinic reports describe a consistent cluster: stronger and more frequent erections, spontaneous arousal without visual stimulation, a "more relaxed and confident" state, and reduced performance anxiety, with the effect window often described as 6–8 hours. Men whose difficulty is performance-anxiety driven report the most striking benefit, which the central mechanism would predict. Reported downsides track the label: flushing, nausea especially on the first dose, headache, and a warm or tingling sensation.
The publisher of this page has used PT-141 and reports that it does act as an effective erectile-dysfunction solution for him, working when he expected it to and without visual stimulation. That is an n = 1 anecdote. It is recorded here because one person's experience is genuine data about what happens in the world — and because pretending otherwise is how people end up trusting the wrong sources. It is not evidence of efficacy for anyone else: there is no control group and no measured endpoint. Tier 2 trials are the reason to believe it might work for you; this paragraph is only the reason it is listed at all.
Because the gap between the label and actual practice is where most questions live. The FDA approves one dose, in one population, on subcutaneous injection; clinicians prescribe off-label at other doses, in men, in other formulations, and patients report effects the trials never measured. Hiding that produces advice nobody follows. Labelling it produces a reader who knows exactly how much each statement is worth.
Four sources settle nearly every question. (1) The FDA prescribing information for Vyleesi (NDA 210557) — the authoritative regulatory text, and the only place a dosing or safety claim is officially sourced. (2) DailyMed (NIH) for the current label rather than an archived copy. (3) PubMed — search "bremelanotide" or "PT-141" and read the abstracts, including the ones cited above. (4) For compounded products, the certificate of analysis from the dispensing pharmacy: HPLC purity, mass-spec identity, USP <71> sterility and USP <85> endotoxin. If a page quotes a number without a citable source, that is itself the finding.
Not lawfully in the U.S. Bremelanotide is prescription-only; compounded versions require a patient-specific prescription after an evaluation, dispensed by a licensed 503A or 503B pharmacy. Products sold as "research chemicals" or "not for human consumption" are not the approved drug, are not dispensed against a prescription, and typically carry no sterility or endotoxin testing — for an injectable, that is the difference that matters.
| Date | What changed | Why |
|---|---|---|
| 2026-11-19 | Added Tier 2 (research) and Tier 3 (reported) in full. Earlier this page implied the intranasal route was unsupported. | Wrong. Intranasal PT-141 was the route in the original male-ED trials, with published PK and efficacy data. The error was conflating "no intranasal data in the label" with "no intranasal data." |
| 2026-11-19 | Added the male-ED evidence base, including the Expression of Concern on the largest trial. | It is the most-asked question and the most-abused answer. |
| 2026-11-19 | Retained the correction that a specific "45% intranasal bioavailability" figure is not an FDA-label figure. | Accurate: the label has no intranasal data. The route is studied; that particular percentage still lacks a label source. |
| 2026-11-19 | Added the publisher's own n = 1 report, explicitly labelled as anecdote. | Transparency about the site's standpoint, without dressing one person's experience as evidence. |